Rapamycin For Longevity With Matt Kaeberlein Robert Lufkin Md They explore the dog aging project, a large scale study testing rapamycin in companion dogs, as well as human evidence related to vaccine response, alzheimer’s risk, and post viral. Founded by dr. matt kaeberlein, a passionate advocate for aging research, this project harnesses the power of citizen science to collect vast amounts of data from dog owners across the united states.
Is Aging Solvable Matt Kaeberlein Rapamycin Longevity News Here, we describe the rationale, design, and goals of the triad randomized clinical trial, the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species. This video is a great talk from dr. matt kaeberlein at raadfest 2025, which took place a few weeks ago in las vegas. the first part of matt’s presentation is a great overview of the dog aging project and why companion animals (dogs) are great organisms to study the biology of aging. On this episode of the healthspan collective podcast, kaeberlein shares how his work moved from studying yeast cells in the lab to launching one of the largest aging studies in the world, the dog aging project. The test of rapamycin in aging dogs (triad) is a double blind, placebo controlled clinical trial of the mtor inhibitor rapamycin, which at low doses has been shown to increase lifespan and delay or reverse many age related disorders in mice.
Details On The Dog Aging Project And Rapamycin Trial Kaeberlein On this episode of the healthspan collective podcast, kaeberlein shares how his work moved from studying yeast cells in the lab to launching one of the largest aging studies in the world, the dog aging project. The test of rapamycin in aging dogs (triad) is a double blind, placebo controlled clinical trial of the mtor inhibitor rapamycin, which at low doses has been shown to increase lifespan and delay or reverse many age related disorders in mice. The rapamycin clinical trial is ongoing, with over 200 dogs enrolled to test whether the drug can slow aging. in the second half of the talk, matt talkes about his role as ceo at optispan, focusing on enabling science based, proactive approaches to extending healthspan in humans. Biogerontologist matt kaeberlein studies aging pets to determine how to improve healthspan in dogs and their humans. daniel promislow and matt kaeberlein are investigating whether rapamycin can increase longevity in companion dogs. hannah joined drug discovery news as an assistant editor in 2022. A small subset of those dogs (approximately 500) will be enrolled in a double blind, placebo controlled study of the pharmaceutical rapamycin, which has shown signs of extending longevity in species such as mice. Tune in as dr. matt kaeberlein describes the longevity agent rapamycin and its impact on mtor and the dog aging project, which is investigating companion dogs as a model organism for aging.
Details On The Dog Aging Project And Rapamycin Trial Kaeberlein The rapamycin clinical trial is ongoing, with over 200 dogs enrolled to test whether the drug can slow aging. in the second half of the talk, matt talkes about his role as ceo at optispan, focusing on enabling science based, proactive approaches to extending healthspan in humans. Biogerontologist matt kaeberlein studies aging pets to determine how to improve healthspan in dogs and their humans. daniel promislow and matt kaeberlein are investigating whether rapamycin can increase longevity in companion dogs. hannah joined drug discovery news as an assistant editor in 2022. A small subset of those dogs (approximately 500) will be enrolled in a double blind, placebo controlled study of the pharmaceutical rapamycin, which has shown signs of extending longevity in species such as mice. Tune in as dr. matt kaeberlein describes the longevity agent rapamycin and its impact on mtor and the dog aging project, which is investigating companion dogs as a model organism for aging.
Comments are closed.